Canada Research Roundup: Centerra Gold, Medexus Pharmaceuticals, Savaria

Medexus Pharmaceuticals

27/03/2020 07:43

March 27 (Reuters) - Securities analysts revised their ratings and price targets on several
Canadian companies, including Centerra Gold, Medexus Pharmaceuticals and Savaria, on Friday. 
    
  HIGHLIGHTS
     * Centerra Gold Inc  CG.TO : Canaccord Genuity raises target price to C$13.50 from C$12
     * Medexus Pharmaceuticals  MDP.V : Canaccord Genuity cuts to speculative buy from buy
     * Savaria Corp  SIS.TO : Scotiabank cuts target price to C$14 from C$16.50
 
Following is a summary of research actions on Canadian companies reported by Reuters on Friday.
Stock entries are in alphabetical order.
     
     * Air Canada  AC.TO : National Bank of Canada cuts target price to C$30 from C$45
     * Centerra Gold Inc  CG.TO : Canaccord Genuity raises target price to C$13.50 from C$12
     * Charlotte'S Web Holdings Inc  CWEB.TO : Eight Capital cuts target price to C$9 from C$13
     * Mav Beauty Brands Inc  MAV.TO : CIBC cuts target price to C$3.50 from C$4.50
     * Medexus Pharmaceuticals  MDP.V : Canaccord Genuity cuts to speculative buy from buy
     * Medexus Pharmaceuticals  MDP.V : Canaccord Genuity cuts target price to C$5 from C$6.50
     * Saputo Inc  SAP.TO : National Bank of Canada cuts target price to C$40 from C$45
     * Saputo Inc  SAP.TO : Scotiabank cuts target price to C$42.50 from C$48.50
     * Savaria Corp  SIS.TO : National Bank of Canada raises target price to C$13 from C$12.50
     * Savaria Corp  SIS.TO : Scotiabank cuts target price to C$14 from C$16.50
    

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))